Biotech BeiGene slides in Shanghai after US$3.5 billion STAR debut

Cancer treatment specialist BeiGene Ltd plunged 16.4per cent on its Shanghai debut on Wednesday after raising US$3.5 billion, hit by concerns over its valuation amid potential U.S. sanctions on …
( read original story …)